About Hairy/enhancer-of-split related with YRPW motif protein 2
Hairy/enhancer-of-split related with YRPW motif protein 2 (HEY2) is a protein
from Homo sapiens identified by UniProt accession
Q9UBP5, 337 residues long.
MolForge cross-references it against 0 known binders and
441 disease associations.
Target properties
| Protein name | Hairy/enhancer-of-split related with YRPW motif protein 2 |
|---|
| UniProt accession | Q9UBP5 |
|---|
| Gene | HEY2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 337 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (441)
Diseases linked to this target (Open Targets).
- lean body mass · score 0.48
- body mass index · score 0.46
- body height · score 0.44
- fat body mass · score 0.43
- body weight · score 0.42
- electrocardiography · score 0.40
- endometrial carcinoma · score 0.39
- familial thoracic aortic aneurysm and aortic dissection · score 0.39
- type 2 diabetes mellitus · score 0.35
- appendicular lean mass · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UBP5-F1 | alphafold | PREDICTED | 64.26 | — |
Amino-acid sequence (337 residues)
MKRPCEETTS ESDMDETIDV GSENNYSGQS TSSVIRLNSP TTTSQIMARK KRRGIIEKRR RDRINNSLSE LRRLVPTAFE KQGSAKLEKA EILQMTVDHL KMLQATGGKG YFDAHALAMD FMSIGFRECL TEVARYLSSV EGLDSSDPLR VRLVSHLSTC ATQREAAAMT SSMAHHHHPL HPHHWAAAFH HLPAALLQPN GLHASESTPC RLSTTSEVPP AHGSALLTAT FAHADSALRM PSTGSVAPCV PPLSTSLLSL SATVHAAAAA ATAAAHSFPL SFAGAFPMLP PNAAAAVAAA TAISPPLSVS ATSSPQQTSS GTNNKPYRPW GTEVGAF
Explore Hairy/enhancer-of-split related with YRPW motif protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets